ABSTRACT
INTRODUCTION
Thyroid gland tumors exhibit a broad spectrum of neoplastic pathology, ranging from benign colloid adenomas to fatal anaplastic carcinomas [1] . Several oncogenes (ras, ret, trk) and tumor-suppressor genes (p53, Rb, p16/CDKN2, p21 waf1 ) have been associated with this kind of tumors. Ras oncogene activation is an early event and appears to be involved in the genesis of follicular adenoma and carcinoma [2] . Three other genetic and/or epigenetic alterations play a role in PTC pathogenesis: activating mutation of ras genes, c-met overexpression and downregulation of Ecadherin in papillary carcinoma. Recently, another major player in papillary carcinoma etiopathogenesis has been reported: the BRAF gene. Papillary carcinoma is one of the human cancers displaying the highest prevalence of BRAF mutations, which occur almost always in the same hot spot (V600E). The finding of a high prevalence of BRAF mutations, together with the involvement of ras mutations and ret/PTC rearrangements in the majority of papillary carcinomas, points to the crucial role played by alterations at the ret/ras/BRAF/MAPK signal transduction pathway in the pathogenesis of papillary carcinoma [3] . Generally, mechanisms governing the transformation of normal thyroid cells into carcinoma are not well understood.
Thyroid epithelium is the second most common tissue type (after blood) where fusion gene products are critical for the early development of cancer [4] . The ret gene is frequently inverted or translocated to form the fusion genes ret/PTCs [5] but those genes alone are insufficient to cause cancer and require the simultaneous or accumulated activation of multiple gene products to progress from early differentiated stages to undifferentiated stages of malignancy. Kresimir Pavelic et al. 4 The FHIT gene, located in 3p14.2 is very often inactivated in various types of cancer [6] [7] [8] . The mechanisms of FHIT inactivations are bialelic deletions, loss of heterozygosity, aberrant methylation, while point mutations are rare [9] [10] [11] . FHIT is encoded at FRA3B, the most frequent fragile site in human genome and FHIT loss is a frequent event in carcinogenesis [8] .
Loss of FHIT protein expression and abnormal FHIT transcripts, including deletions of exons and insertions, are found in a high percent in lung and breast cancers [6, [12] [13] [14] as well as in head and neck cancers [15] . FHIT is a putative tumor suppressor and belongs to the histidine triad superfamily of nucleotide-binding proteins. Re-expression of FHIT in cancer cell lines with FHIT-deletions suppressed their ability to form tumors in mice [16] . Analysis of preneoplastic and neoplastic lesions from the lungs of smokers has indicated that events that lead to lack of expression of FHIT are the earliest and the most frequent identified genetic changes in lung cancers [6] .
Several studies indicate the aberration of FHIT gene in thyroid cancer. McIver control in immunohistochemical studies, we used paraffin slides of the lung cancer positive for FHIT protein.
The localization and level of specific immunostaining for each slide was evaluated in the whole tumor area. The relative level of specific immunostaining and its localization were judged. The relative intensity of cell immunostaining was evaluated semiquantitatively, so that no staining was denoted (0), weak staining was denoted (1), moderate (2) , and strong (3). Each sample was assessed independently by two observers. There was a 95 % initial agreement between them.
Loss of heterozigosity analysis
Tumor DNAs were extracted from frozen tumor tissue obtained during routine surgery of patients with thyroid gland lesions and stored at -80°C. All tumor specimens were examined by routine hematoxylin-eosin staining to determine the proportion of tumor cells in the sample (it had to be more than 80%). Control normal DNA was extracted from peripheral blood of patients. Frozen-tissue and blood DNA extraction was performed using proteinase K digestion and phenol chloroform extraction.
To analyze LOH at the FHIT gene locus, we used D3S1300 dinucleotide repeat and D3S4103 trinucleotide repeat and VNTR analysis as it was described previously [15] . LOH at the p53 gene locus was also anlyzed by VNTR analysis and highly informative exogenic (CA) n repeat as it was previously described [21] .
LOH was defined by visible change in allele:allele ratio in tumors compared with matching normal tissue. Allelic deletion of FHIT was judged by a positive LOH at any of the two sites. 
RNA extraction and reverse transcription
Total RNA from tissues was extracted using RNAzol 
FHIT gene expression analysis
The FHIT gene expression analysis was performed by nested RT-PCR method as it was described previously [15] . Half of microliter of cDNA was used for PCR amplifications with primers 5U2 and 3D2 from FHIT exons 1 and 10, respectively. Final extension lasted 10 min. Two microliters of first PCR products were used for nested PCR amplifications with primers 5U1 and 3D1 from FHIT exons 3 and 10, respectively. The PCR products were resolved by agarose gel electrophoresis (1.5% agarose stained with 0.5 µg/ml ethidium bromide). RT-PCR products were directly sequenced after isolation of bands from low melting agarose and purification on columns. The sequencing of aberrant PCR products was performed as described previously [22] . 
Analysis of apoptosis

Cultivation of primary carcinoma cells
Surgical specimens were collected into sterile vessels containing RPMI 1640 medium with 10% heat inactivated fetal calf serum and 5% human serum. Informed consent was obtained from all patients from whom surgical specimens were obtained. (Table 1) .
On the contrary, the most malignant thyroid lesions were negative for FHIT protein, 59 (48 %) of 124 examined. The majority of follicular carcinoma (50%), medullary carcinoma (68%), anaplastic carcinoma (73%) samples showed a negative FHIT protein expression. Only in papillary carcinoma majority of samples (44%) showed strong immunohistochemical staining of FHIT protein (Table 1 )( Figure 1C and 1D).
Loss of heterozygosity
One hundred sixty and five samples of benign (30 samples To analyze LOH at the p53 gene we used highly informative exogenic (CA) n repeat. The LOH of p53 gene was also more frequent in malignant than in benign (Table 3 and 4). Anaplastic carcinomas displayed mutations in FHIT gene in almost all cases.
Deletions were found in 5 cases and insertions in 3 cases of anaplastic carcinomas. In 5 malignant tumors FHIT gene status was not analyzed (Table 4) .
FHIT gene expression and apoptosis
Results of FHIT gene expression in malignant thyroid tumors were correlated with the rate of apoptosis in the same tumors. The rate of apoptosis in tumors with normal FHIT transcript was between 35% and 68% (mean value 57.4%) and in tumors with aberant transcripts was between 6% and 28% (mean value 16.7%). There was statistically significant lower rate of apoptosis in tumors with aberrant FHIT transcripts (p<0.01) (Figure 4 ).
p53 gene mutation analysis
Results of p53 gene mutation analysis in benign lesions are summarized in Table 2 . The majority of benignant thyroid lesions do not display mutation in p53 Table 4 ). The point mutation GTA>GAA at p53 gene codon 193 (His>Leu) was found in one anaplastic carcinoma, but in extranodular metastasis of the same tumor another mutation, GGC>GGT at the p53 gene codon 248, was found ( Figure 5 ). Kresimir Pavelic et al. 16 Anaplastic tumors which harbored mutations in both genes displayed relative low percentage of apoptosis but not statistically significant ( Figure 6 ). (Figure 7 ) and mice survival rate was shorter.
Tumorigenicity in nude mice
Discussion
Our results showed that FHIT gene is disrupted in thyroid lesions and hence, loss of FHIT protein function, together with aberration of p53 gene, increased tumor cell proliferation and low rate of apoptosis may be important in the development and/or progression of thyroid cancer. Recently we obtained similar results on head and neck sqamous cell carcinomas [15] . We also found higher incidence of p53 mutation and aberrant processing of FHIT mRNA in more advanced undifferentiated tumors (in metastatic papillary and follicular, medullary and particularly in anaplastic carcinomas).
The pattern of abnormal FHIT transcript in our present study as well as in Zou et al study [2] is similar to those reported in lung, breast and head and neck cancers In our study results of FHIT gene expression in malignant thyroid tumors were correlated with the rate of apoptosis in the same tumors. The rate of apoptosis in tumors with normal FHIT transcript was between 35% and 68% (mean value 57.4%) and in tumors with aberant transcripts was between 6% and 28% (mean value 16.7%).
There was statistically significant lower rate of apoptosis in tumors with aberrant FHIT transcripts (p<0.01). Kresimir Pavelic et al. 19 The inactivation of tumor suppressor genes is considered to be a critical event in the multi-step genetic process leading to the development of most cancers [28, 29] .
Loss of heterozygosity in FHIT locus is relatively frequent event in thyroid cancer as one of the mechanisms for inacivation in this gene. Several authors have investigated the incidence of LOH in thyroid neoplasms [30, 31] . Zou found the highest incidence of LOH in follicular carcinomas, with chromosome 2p and 3p the most frequently affected sites. Fine mapping of 3p showed LOH clustered in the telomeric region (3p21-ter) as well as at D3S1300 (3p14.2) where FHIT was located [2, 32] . LOH in 3p.14.2 region is highly localized to the microsatellite marker D3S1300, which displayed LOH in 73% of informative cases, while neighbouring microsatellite markers (D3S1234, D3S1481, D3S1480) had much lower rates of LOH (14-44%).
This suggests selective allelic deletion in the D3S1300 region [17] .
LOH of FHIT gene has been associated with both benign and malignant thyroid lesions suggesting that FHIT aberration may be an early event in development of thyroid cancer [2, 33] , although some data do not support an association between FHIT loss and the stage, histological grade or outcome in human thyroid cancer. Our data suggest strong difference in the FHIT aberration between benign and malignant thyroid lesions. Benign lesions have much less incidence of FHIT loss in comparison to malignant. Follicular carcinomas in our study show relatively high incidence of LOH at FHIT loci.
There is considerable controversy concerning when p53 mutations arise during thyroid tumor development [34] [35] [36] . The p53 gene has been implicated as a tumor suppressor gene whose inactivation by mutation has been noted in a variety of human malignancies. Cultured cells harboring p53 mutations are unable to grow when transplanted in vivo [37] suggesting that the timing of p53 mutation is a crucial step in tumor progression. Some data have shown that p53 affects proliferative capabilities of thyroid cells in vitro [38] . Loss of p53 function could lead to genome destabilization promoting development of additional mutations [5] . 
